المصدر: Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05904730Test

Other URLs: https://pubmed.ncbi.nlm.nih.gov/24755544Test/
https://www.pennmedicine.org/news/news-releases/2022/november/why-cancers-caused-by-brca-mutations-recurTest
https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-021-00193-yTest

المصدر: PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05868226Test

المصدر: Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05511844Test

المصدر: Klhsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmrer M, Gabruswz K, Anderson NR, Petty NE, Cumms KD, Shen F, Shan X, Vel K, Blouch K, Yasho-OhtanY, Kendern SS, K MY, O'Connor RS, Wallace SR, KozlowskMS, Marchne DM, Shestov M, Garc BA, June CH, Gl S. Human cher anten receptor macrophages for cancer munotherapy. Nat Btechnol. 2020 Aug;38(8):947-953. do 10.1038/s41587-020-0462-y. Epub 2020 Mar 23.
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04660929Test

المصدر: A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04650451Test

المؤلفون: Byondis B.V.

المصدر: ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04602117Test

المصدر: A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Vivo Expanded, Autologous Natural Killer Cells (SNK01) in Combination With Trastuzumab or Cetuximab in Subjects With Advanced/Metastatic HER2- or EGFR-Expressing Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04464967Test

المصدر: Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03630809Test